BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
Press Release|Articles|August 4, 2025
Camber Launches Colchicine Capsules
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals has launched Colchicine Capsules for gout flare prophylaxis in adults, expanding its generic drug portfolio.
- Colchicine inhibits natural processes causing swelling and symptoms of gout, offering effective management.
Advertisement
As a leader in generic drug approvals and launches, Camber Pharmaceuticals is excited to announce the addition of Colchicine Capsules [coll-chi-seen] to its current portfolio.
Colchicine Capsules are indicated for prophylaxis of gout flares in adults. Colchicine works by stopping the natural processes that cause swelling and other symptoms of gout.
Colchicine Capsules are available in 0.6 mg, 30- and 100-count bottles.
To learn more about Colchicine Capsules, please visit:
Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement